Nexstim Oyj
Company announcement, Helsinki, 19 February 2021 at 9.00 am (EET)
Notice of Nexstim Plc 2020 Full Year Results
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") will announce its full year results for the year ended 31 December 2020 on Friday 26 February 2021 at 9.00 am Finnish time.
The company will hold two live webinars for media, investors and analysts on Friday 26 February 2021. Mikko Karvinen CEO, and Joonas Juokslahti CFO, will present the financial and operational results followed by a Q&A session.
The first live webinar will be in Finnish and it takes place at 1 pm EET. The second live webinar will be in English at 3 pm EET.
Webinar details:
To attend the webinars, please register via the links below. Registered participants will receive more information to their e-mail.
Live Webinar in Finnish on 26 February 2021 at 1 pm (EET): Register here >>>
Live Webinar in English on 26 February 2021 at 3 pm (EET): Register here >>>
NEXSTIM PLC
Mikko Karvinen, CEO
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+ 358 50 326 4101
mikko.karvinen@nexstim.com
Erik Penser Bank AB (Certified Adviser)
+46 8 463 83 00
certifiedadviser@penser.se
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information please visit www.nexstim.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Sodexo SA1.7.2025 07:00:00 CEST | Press release
Sodexo Q3 Fiscal 2025 revenues in line with expectations
dsm-firmenich1.7.2025 07:00:00 CEST | Press release
dsm-firmenich announces redemption of €750 million hybrid bond
dsm-firmenich1.7.2025 07:00:00 CEST | Press release
Weekly progress on share repurchase program to cover share plans and reduce capital
Atico Mining Corporation30.6.2025 22:29:54 CEST | Press release
Atico Mining Announces Execution of Loan Amendment with Trafigura to Restructure Outstanding Credit Facility
Top California Lender30.6.2025 22:02:33 CEST | Press release
Top California Lender Welcomes New Investors to Fuel Expanded Lending Capacity
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom